ReviewExpert opinion on drug discovery2012
Drug discovery technologies and strategies for Machupo virus and other New World arenaviruses.
Review in Expert opinion on drug discovery, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- Junín virus and Argentine haemorrhagic fever: Virology, pathogenesis, diagnosis, and prevention strategies.World journal of virology · 2026Review
- Understanding machupo virus: A neglected arenavirus with global health importance.World journal of virology · 2026Review
- Inhibitors of the Machupo Virus L Endonuclease for Bolivian Hemorrhagic Fever Treatments.Microorganisms · 2026Article
- Immunoinformatics-driven design of a multi-epitope vaccine for effective protection against Machupo virus.Molecular diversity · 2026Article
- Treatment of highly virulent mammarenavirus infections-status quo and future directions.Expert opinion on drug discovery · 2024Review
- Article
- An updated review and current challenges of Guanarito virus infection, Venezuelan hemorrhagic fever.Archives of virology · 2022Review
- Isolation of Reconstructed Functional Ribonucleoprotein Complexes of Machupo Virus.Journal of virology · 2021Article
- Structure of Machupo virus polymerase in complex with matrix protein Z.Nature communications · 2021Article
- Tuning the binding interface between Machupo virus glycoprotein and human transferrin receptor.Proteins · 2021Article
- Native functionality and therapeutic targeting of arenaviral glycoproteins.Current opinion in virology · 2016Review
- Evaluation of transmission risks associated with in vivo replication of several high containment pathogens in a biosafety level 4 laboratory.Scientific reports · 2014Article
- Small-molecule probes targeting the viral PPxY-host Nedd4 interface block egress of a broad range of RNA viruses.Journal of virology · 2014Article
- A host-oriented inhibitor of Junin Argentine hemorrhagic fever virus egress.Journal of virology · 2014Article
- Vaccine Platforms to Control Arenaviral Hemorrhagic Fevers.Journal of vaccines & vaccination · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
introductionSeven arenaviruses cause viral hemorrhagic fever in humans: the Old World arenaviruses Lassa and Lujo, and the New World Clade B arenaviruses Machupo (MACV), Junín (JUNV), Guanarito (GTOV), Sabiá (SABV), and Chapare (CHPV). All of these viruses are Risk Group 4 biosafety pathogens. MACV causes human disease outbreak with high case-fatality rates. To date, at least 1,200 cases with ≈200 fatalities have been recorded. AREAS COVERED: This review summarizes available systems and technologies for the identification of antivirals against MACV. Furthermore, the article summarizes animal models that have been used for the in vivo evaluation of novel inhibitors. The article highlights present treatments for arenaviral diseases and provides an overview of efficacious small molecules and other therapeutics reported to date. Finally, the article summarizes strategies to identify novel inhibitors for anti-arenaviral therapy. EXPERT OPINION: New high-throughput approaches to quantitate infection rates of arenaviruses, as well as viruses modified to carry reporter genes, will accelerate compound screens and drug discovery efforts. RNAi, gene expression profiling and proteomics studies will identify host targets for therapeutic intervention. New discoveries in the cell entry mechanism of MACV and other arenaviruses as well as extensive structural studies of arenaviral L and NP could facilitate the rational design of antivirals effective against all pathogenic New World arenaviruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.